ECSP077422A - Derivado de bencimidazol ariloxi-sustituido - Google Patents

Derivado de bencimidazol ariloxi-sustituido

Info

Publication number
ECSP077422A
ECSP077422A EC2007007422A ECSP077422A ECSP077422A EC SP077422 A ECSP077422 A EC SP077422A EC 2007007422 A EC2007007422 A EC 2007007422A EC SP077422 A ECSP077422 A EC SP077422A EC SP077422 A ECSP077422 A EC SP077422A
Authority
EC
Ecuador
Prior art keywords
atom
group
indicates
treatment
substituted
Prior art date
Application number
EC2007007422A
Other languages
English (en)
Inventor
Noriaki Hashimoto
Keiji Takahashi
Fumiko Sakai
Teruyuki Nishimura
Jun-Ichi Eiki
Yoshio Ogino
Chisato Nakama
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of ECSP077422A publication Critical patent/ECSP077422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un activador de glucoquinasa; y se proporciona un tratamiento y/o prevención para la diabetes, o un tratamiento y/o prevención para complicaciones de la diabetes tales como retinopatía, nefropatía, neurosis, cardiopatía isquémica, arteriosclerosis, y un tratamiento y/o prevención adicional para la obesidad. La invención se refiere a un compuesto de fórmula (I):[en la que R1 y R2 representa hidrógeno, etc.; R3 representa un átomo de hidrógeno, un átomo de halógeno, etc.; cada R4 representa independientemente un átomo de hidrógeno, un grupo alquilo inferior, etc.; Q representa un átomo de carbono, un átomo de nitrógeno o un átomo de azufre (el átomo de azufre puede estar mono- o di-sustituido con un grupo oxo); cada uno de R5 y R6 representa un átomo de hidrógeno, un grupo alquilo inferior, etc.; cada uno de X1, X2, X3 y X4 representa independientemente un átomo de carbono o un átomo de nitrógeno; Z representa un átomo de oxígeno, un átomo de azufre o un átomo de nitrógeno; Ar representa un grupo arilo o heteroarilo opcionalmente de mono a tri-sustituido con un grupo seleccionado entre el grupo de sustituyentes b; el anillo A representa un grupo heteroaromático, que contiene nitrógeno, de 5 ó 6 miembros; m indica un número entero de 1 a 6; n indica un número entero de 0 a 3; p indica un número entero de 0 a 2 (con la condición de que al menos dos de X1 a X4 sean átomos de carbono); q indica 0 ó 1] o su sal farmacéuticamente aceptable, que tiene un efecto de activación de glucoquinasa y es útil como tratamiento para la diabetes.
EC2007007422A 2004-11-02 2007-04-27 Derivado de bencimidazol ariloxi-sustituido ECSP077422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004319339 2004-11-02
JP2005178628 2005-06-17

Publications (1)

Publication Number Publication Date
ECSP077422A true ECSP077422A (es) 2007-05-30

Family

ID=36319300

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007422A ECSP077422A (es) 2004-11-02 2007-04-27 Derivado de bencimidazol ariloxi-sustituido

Country Status (17)

Country Link
US (1) US7932394B2 (es)
EP (1) EP1810969B1 (es)
JP (1) JP5036316B2 (es)
KR (1) KR20070083939A (es)
CN (1) CN101094847B (es)
AU (1) AU2005301608B2 (es)
BR (1) BRPI0517232A (es)
CA (1) CA2586056C (es)
CR (1) CR9078A (es)
EC (1) ECSP077422A (es)
IL (1) IL182679A0 (es)
MA (1) MA29043B1 (es)
MX (1) MX2007005289A (es)
NO (1) NO20072806L (es)
NZ (1) NZ554440A (es)
RU (1) RU2398773C2 (es)
WO (1) WO2006049304A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4707560B2 (ja) * 2003-12-29 2011-06-22 Ｍｓｄ株式会社 新規２−ヘテロアリール置換ベンズイミダゾール誘導体
US7994331B2 (en) 2005-07-13 2011-08-09 Msd K.K. Heterocycle-substituted benzimidazole derivative
EP1963259B1 (en) * 2005-12-15 2012-02-15 AstraZeneca AB Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ES2373181T3 (es) 2007-01-04 2012-02-01 Prosidion Ltd Agonistas de gpcr de piperidina.
WO2009018657A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2221301B1 (en) 2007-11-12 2014-06-04 Msd K.K. Heteroaryloxy quinazoline derivative
CN103483251A (zh) 2007-12-19 2014-01-01 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
CN101896483B (zh) 2007-12-20 2013-11-20 株式会社Lg生命科学 葡糖激酶激活剂和包含其作为活性成分的药物组合物
US8592428B2 (en) 2008-08-15 2013-11-26 Msd K. K. Acetyl pyrrolidinyl indole derivative
AU2009285194A1 (en) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co.,Ltd. Oxotetrahydrofuran-2-yl-benzimidazole derivative
CN101607923B (zh) * 2009-07-21 2012-12-19 焦宁 芳基腈类化合物或其衍生物及其合成方法和应用
SG190784A1 (en) * 2010-11-09 2013-07-31 Fujian Haixi Pharmaceuticals Inc Compound for increasing kinase active and application thereof
US20120258891A1 (en) * 2011-04-07 2012-10-11 Nimblegen Systems Gmbh Diarylsulfide backbone containing photolabile protecting groups
WO2015161016A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Bicyclic cgrp receptor antagonists
CN108882709A (zh) * 2015-11-17 2018-11-23 美国陶氏益农公司 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-氧代乙基)吡啶-3-基)氧基)苄腈以及制备方法
CN108882708A (zh) * 2015-11-17 2018-11-23 美国陶氏益农公司 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-羟基-3-(1h-1,2,4-三唑-1-基)丙基)吡啶-3-基)氧基)苄腈以及制备方法
WO2017087643A1 (en) * 2015-11-17 2017-05-26 Viamet Pharmaceuticals, Inc. 4-((6-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
KR102446529B1 (ko) * 2017-01-10 2022-09-23 에테하 취리히 세포 보호 화합물 및 이의 용도
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2024033677A1 (en) * 2022-08-09 2024-02-15 Faculdade De Farmácia Da Universidade De Lisboa One-pot method for the synthesis of 3-acetamido-furfural from n-acetylglucosamine
JP7356203B1 (ja) * 2023-08-03 2023-10-04 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 ＷＤ ａｎｄ ｔｅｔｒａｔｒｉｃｏｐｅｐｔｉｄｅ ｒｅｐｅａｔｓ １遺伝子発現亢進用医薬組成物及び食品組成物
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DK337086A (da) * 1985-08-12 1987-02-13 Hoffmann La Roche Benzimidazolderivater
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US20020032330A1 (en) * 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
JPH10306076A (ja) 1997-03-06 1998-11-17 Nippon Chemiphar Co Ltd プロピオン酸誘導体
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20020060067A (ko) * 1999-04-06 2002-07-16 가와무라 요시부미 α-치환 카르복실산 유도체
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
ATE316965T1 (de) * 2000-12-06 2006-02-15 Hoffmann La Roche Kondensierte heteroaromatische glucokinaseaktivatoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003254795A1 (en) 2002-08-02 2004-02-23 Sankyo Company, Limited Resorcinol derivative
JP2004123711A (ja) 2002-08-02 2004-04-22 Sankyo Co Ltd レゾルシノール誘導体
JP2004067629A (ja) 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
JP4707560B2 (ja) * 2003-12-29 2011-06-22 Ｍｓｄ株式会社 新規２−ヘテロアリール置換ベンズイミダゾール誘導体

Also Published As

Publication number Publication date
EP1810969A1 (en) 2007-07-25
JP5036316B2 (ja) 2012-09-26
EP1810969A4 (en) 2011-05-25
US7932394B2 (en) 2011-04-26
MX2007005289A (es) 2007-07-19
NZ554440A (en) 2010-01-29
BRPI0517232A (pt) 2008-10-07
AU2005301608B2 (en) 2012-09-13
MA29043B1 (fr) 2007-11-01
NO20072806L (no) 2007-07-27
WO2006049304A1 (ja) 2006-05-11
CA2586056A1 (en) 2006-05-11
US20080125429A1 (en) 2008-05-29
IL182679A0 (en) 2007-09-20
EP1810969B1 (en) 2013-08-07
RU2007120519A (ru) 2008-12-10
KR20070083939A (ko) 2007-08-24
CA2586056C (en) 2012-03-13
CR9078A (es) 2007-10-01
CN101094847B (zh) 2011-06-15
CN101094847A (zh) 2007-12-26
JPWO2006049304A1 (ja) 2008-05-29
AU2005301608A1 (en) 2006-05-11
RU2398773C2 (ru) 2010-09-10

Similar Documents

Publication Publication Date Title
ECSP077422A (es) Derivado de bencimidazol ariloxi-sustituido
ES2524045T3 (es) Nuevas amidas y tioamidas heteroaromáticas como plaguicidas
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
AR056548A1 (es) Derivados de sulfonamidas, composiciones farmaceuticas y sus usos
EA200970478A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
BR0112658A (pt) Ativadores de benzeno-acetamida-glucoquinase substituìdos por alfa-acil e alfa heteroátomos
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
ES2572155T3 (es) Compuestos insecticidas
MY169179A (en) Novel piperidine compound or salt thereof
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR056109A1 (es) Derivados de tiazolopiridina como activadores de la actividad de glucoquinasa
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
CO6160266A2 (es) Derivado de oxopirazina y herbicida
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
ECSP066682A (es) Derivado novedoso de bencimidazol 2-heteroaril-substituido
TN2009000129A1 (en) Indole compound
EA200870362A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
MY152972A (en) Azabicyclo compound and salt thereof
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
TW200639158A (en) New compounds with therapeutic effect
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.